GlassScriptPhysician profile
George B Bryant
NPI 1285625921
$1,643.22
in general payments reported to CMS, 2019-2025
17 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $187 · 2023: $424 · 2024: $378 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.75 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $438.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $271.36 | 2021-2025 | Mounjaro, Trulicity |
| Amgen INC. | $203.87 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $191.97 | 2022-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $74.21 | 2024 | |
| Glaxosmithkline, LLC. | $67.00 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.74 | 2022-2024 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $51.19 | 2021 | |
| Bioxcel Therapeutics, INC. | $48.52 | 2023 | Igalmi |
| Esperion Therapeutics, INC. | $44.20 | 2021-2025 | Nexletol |
| Pfizer INC. | $44.19 | 2024-2025 | |
| Dexcom, INC. | $40.91 | 2023-2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $34.06 | 2021-2025 | Vest Therapy Und |
| Abbvie INC. | $23.63 | 2025 | |
| Abbott Laboratories | $21.43 | 2023 | Freestyle Libre 2 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.88 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.